Illinois Business Review
SEE OTHER BRANDS

Your business and economy news reporter from Illinois

Illinois Business Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Business Review.

Press releases published on June 6, 2025

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence– Hagens Berman

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence– Hagens Berman

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and …

Pilly Labs Presents Natural Single-Ingredient Supplement Line Focused on Holistic Wellness

Pilly Labs Presents Natural Single-Ingredient Supplement Line Focused on Holistic Wellness

Chicago, June 06, 2025 (GLOBE NEWSWIRE) -- Pilly Labs, a natural wellness company dedicated to harnessing the power of nature, announces the release of its comprehensive line of single-ingredient supplements designed to enhance overall well-being through …

INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into EchoStar Corporation (SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into EchoStar Corporation (SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman …

Marimaca Announces Results of Annual General Meeting of Shareholders

Marimaca Announces Results of Annual General Meeting of Shareholders

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) is pleased to announce the results of the votes cast by ballot at its Annual General Meeting of Shareholders held …

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …

Magnetic North Acquisition Corp. Provides Bi-Weekly Update On Status Of Management Cease Trade Order

Magnetic North Acquisition Corp. Provides Bi-Weekly Update On Status Of Management Cease Trade Order

CALGARY, Alberta and TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on May 9 …

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to July 9, 2025

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to July 9, 2025

New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 …

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences

Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th …

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology …

NPWR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NET Power Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NPWR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NET Power Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …

Northann Corp. Issues Statement on Recent Stock Volatility

Northann Corp. Issues Statement on Recent Stock Volatility

Fort Lawn, SC, June 06, 2025 (GLOBE NEWSWIRE) -- Northann Corp. (“Northann” or the “Company”) (NYSE American: NCL), a company specializing in 3D printing and manufacturing solutions, today announced that it is not aware of any new material developments or …

NIRI Florida Announces its 2025-2026 Board of Directors

NIRI Florida Announces its 2025-2026 Board of Directors

Fort Lauderdale, FL, June 06, 2025 (GLOBE NEWSWIRE) -- The Florida Chapter of NIRI: The Association for Investor Relations is pleased to announce the election of the following individuals to serve on the Board of Directors for the 2025-2026 program year: …

XOVR ETF Adds Anduril, Joining SpaceX to Offer Pre-IPO Access

XOVR ETF Adds Anduril, Joining SpaceX to Offer Pre-IPO Access

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- ERShares, the first Crossover ETF that offers retail investors access to Private companies, with SpaceX as its top weight, is ushering in the next generation of investing with a new private equity position in …

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert …

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments ( …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service